Little Green Pharma has launched its first dried flower cannabis medicine to help meet increasing patient demand and plug the flower shortage.

LGP’s flower product complements its range of cannabis oils

LGP Flower THC 22 – Desert Flame is a Schedule 8 medicine with 22% THC and less than 1% CBD. The product is available in a 15g container and is expected to be prescribed via inhalation using a vaporiser. It complements LGP’s existing medicinal cannabis oil product range.

Managing director Fleta Solomon said: “Flower medicines are becoming increasingly popular with Australian doctors in prescribing to patients for quick onset of effects, mainly for breakthrough pain or to assist with sleep.

“Importantly with this product, we are providing a new supply of high-quality, Australian-grown medicinal cannabis flower in an under-supplied market, to assist prescribed patients with access to their medicine.”

Prior to launching Cannabiz, Martin was co-founder and CEO of Asia-Pac’s leading B2B media and marketing information brand Mumbrella, overseeing its sale to Diversified Communications in 2017. A journalist...